Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.69 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.69 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19556669 | 0.93 | SLC22A12 (0.74) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL18979018 | 0.85 | SLC22A12 (0.88) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL18979101 | 0.83 | SLC22A12 (0.86) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL19240212 | 0.81 | SLC22A12 (0.66) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL15164011 | 0.81 | SLC22A12 (0.83) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL29362845 | 0.81 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL12070797 | 0.81 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL17541410 | 0.81 | SLC22A12 (0.65) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL18979023 | 0.80 | SLC22A12 (0.69) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL21828465 | 0.80 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | InventisBio Co., Ltd. (CN) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CA7, CYP2C9, CA9 | SLC22A12 251/4885SLC22A6 205/4885SLC22A11 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.